during the forecast period (2024 - 2032). The key factors driving the expansion of the intravenous solution market include rising chronic disease incidence and prevalence, an aging global population, and rapidly increasing healthcare spending on IV therapy treatment.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Intravenous Solution Market Trends
New intravenous injection solutions are being introduced by market participants, which is anticipated to accelerate the growth of the global intravenous solutions market in the upcoming years. For example, Baxter International Inc., a global sterile medication production company, announced the FDA approval and commercial launch of premix Bitartrate in 5% Dextrose Injection in September 2021. In adults with severe, acute hypotension, is prescribed to raise blood pressure (low blood pressure). Baxter's formulation is the first and only producer of ready-to-use formulation available in four strengths: 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL).
Parenteral (intravenous) nutrition (PN) product launches by key market players for developing global intravenous solutions are anticipated to propel market growth in the forecast period. For instance, in June 2019, the Indian pharmaceutical market saw the introduction of the intravenous IV products Lifeport and Discport by Eurolife Healthcare, a manufacturer and distributor of specialty infusion & pharmaceuticals. The product, which uses advanced technology to lower the risk of infection, is regarded as a smart intravenous infusion.
The rising prevalence of malnutrition, shorter response time, and higher efficacy associated with intravenous solution therapy have further contributed to expanding the intravenous solution market share.
Intravenous Solution Market Segment Insights:
Intravenous Solution Nutrition Type Insights
Based on the nutrition type, the intravenous solution market segmentation includes peripheral and total parenteral nutrition. The total parenteral nutrition (TPN) segment had the largest share in 2021, accounting for nearly 62-66% of intravenous solution market revenue, owing to higher adoption for patients who do not receive any other form of nutrition. This is brought on by increased gastrointestinal conditions like Ulcerative Colitis (UC) and Crohn's Disease (CD), which prevent patients from absorbing vital nutrients. Therefore, an intravenous route is used to deliver these vital nutrients. The increase in the elderly population, where patients need to be fed nutritionally necessary products via intravenous routes, can also be attributed to segment growth.
Figure 2: Intravenous solution market, by Nutrition Type, 2021 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Intravenous Solution Bag Type Insights
Based on the bag type, the intravenous solution market includes large-volume bags (>250 ml) and small-volume bags (<250 ml). The small-volume bags (<250 ml) segment had the largest global market revenue share in 2021. Globally, a rise in patients with various types of infectious diseases is a major factor driving the growth of this segment. They are also becoming more popular in blood bank centers to meet emergency blood infusion needs and treat various blood-borne diseases. In addition, IV fluid bag manufacturers create PVC-free bags made of non-latex elements to safely and accurately deliver IV fluids. Cold, frozen, and customized mixtures can also be stored in these fluid bags.
Intravenous Solution Nutritional Content Insights
Based on the nutritional content, the intravenous solution market segmentation includes amino acid solutions, carbohydrates, vitamins & minerals, parenteral lipid emulsion, and others. The amino acid solution segment had the highest revenue share in 2021, owing to the rising prevalence of nutrient deficiencies and hepatic diseases and higher consumption of amino acid injections. The increased approval of enhanced amino acid solutions with fewer side effects propels the intravenous solution market forward. The increasing utility of parenteral nutrition regimens and single doses based on amino acids in the preparation of intravenous parenteral fluids worldwide is a key factor contributing to the growth of this segment.
Intravenous Solution End User Insights
Based on the end user, the intravenous solution market segment includes hospitals & clinics, ambulatory surgical centers, and home care. The hospital & clinics segment had a significant market revenue share in 2021 due to an increase in the number of hospitals and clinics and an increase in the prevalence of metabolic problems. The growing number of patients who undergo surgical procedures that require IV solutions as a post-therapy routine for various conditions and diseases in hospitals worldwide is expected to drive the Intravenous (IV) Solutions market size during the forecast period.
Intravenous Solution Regional Insights
By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North American intravenous solution market is expected to grow at a significant CAGR during the projection period, accounting for USD 2.8 billion in 2021. This is due to an increase in the geriatric population, which increases demand for intravenous solutions, the rising incidence of chronic diseases, and the industry's expansion to meet the rising demands caused by the flu and coronavirus pandemics. North America is a highly developed region with a well-established healthcare infrastructure, which has resulted in an increased demand for IV treatment throughout its life cycle during various stages, such as emergency care or surgery.
In addition, the major countries covered in the intravenous solution market are the United States, Germany, France, Canada, the United Kingdom, India, Spain, Italy, Japan, Australia, China, South Korea, and Brazil.
Figure 3: Intravenous Solution Market Share By Region 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe has the world's second-largest intravenous solution market, owing to increasing intravenous solution sales volume in the region due to the region's aging population and correlating growth of the patient pool. This is because the healthcare system has a large patient population, a strong presence of key players, easy drug availability, well-developed healthcare systems, and favorable reimbursement policies. Moreover, technological advancements in the industry and government assistance for the National Health Service and health insurance will likely drive growth in the European intravenous (IV) solutions market. Further, the U.K. intravenous solution market held the largest market share, and the France intravenous solution market was the fastest-growing market in the European region.
The Asia Pacific intravenous solution market is predicted to expand at the fastest CAGR in the forecast period. The presence of high expenditure by both public and private entities in the research sector, as well as technological advancements and an increasing number of collaborative relationships between various stakeholders, such as the healthcare community, universities, and others, can be attributed to this region's rapid growth. Another important factor anticipated to drive market growth in the Asia Pacific region is the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing preference for cost-effective care.
Intravenous Solution Key Market Players & Competitive Insights
The market players constantly expand their facilities, collaborate, acquire companies, and develop new products. These are major strategic initiatives influencing the dynamics of the intravenous solution industry. Additionally, the prevalence of chronic diseases is rising, offering huge opportunities to manufacturers of intravenous solutions. The main industry players concentrate on research and development activities to release new and effective treatments, accelerating the market's growth.
ICU Medical Inc, headquartered in San Clemente, California, develops, manufactures, and sells medical technologies for oncology, vascular therapy, and critical care applications. Smith’s Medical, a division of Smiths Group plc, was acquired by ICU Medical in January 2022. This merger will add Smiths Medical's ambulatory infusion equipment, syringes, vascular access, and medical supplies to ICU Medical's current infusion therapy system, generating an estimated pro forma revenue of about USD 2.5 billion.
The company B. Braun Medical (India) Private Ltd sells medical supplies. The company produces instruments and equipment for medicine, surgery, ophthalmology, diabetes care, infection control, ostomy care, infusion therapy, and veterinary medicine. International customers are served by B. Braun Medical (India). B. Braun Medical received permission from the US FDA in February 2022 to start operations at its brand-new IV saline solution production plant in Daytona Beach, Florida.
Key Companies in the intravenous solution market include
- Baxter International Inc (US)
- Fresenius SE & Co. KGaA (Germany)
- Braun Melsungen AG (Germany)
- ICU Medical Inc (US)
- Pfizer Inc (US)
- Grifols S.A. (Spain)
- Terumo Medical Corporation (Japan)
Intravenous Solution Industry Development
November 2023:The U.S. Food and Drug Administration (FDA) approved Grifols, S.A (Spain) Gamunex-C immunoglobulin (Ig) purification and filling facility at its manufacturing campus in Clayton, North Carolina. to treat primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. If you have PIDD, you may take GAMUNEX-C under the skin (subcutaneously) or in a vein (intravenously).
November 2023:Fresenius Kabi (Germany) introduces tyenne, a biosimilar to cilizumab. Tyenne presents a better, more economical, and safer option for tocilizumab-using European patients compared to their current course of treatment. In Europe, Tyenne is the third biosimilar to Fresenius Kabi that has been approved and is accessible for intravenous and subcutaneous injection.
October 2023:B. Braun Melsungen AG (Germany) introduced the Introcan Safety 2 IV Catheter with Multi-Access Blood Control. The Introcan Safety 2 IV Catheter is the newest model in B. Braun's wide selection of passive needlestick prevention catheters.
April 2023:Baxter International Inc (US) launched ZOSYN (piperacillin and tazobactam) Injection In the US. Zosyn premix is an important addition to Baxter’s portfolio of valuable anti-infective medications that help treat some of the most pressing healthcare needs facing patients.
September 2022: B. Braun Medical Inc has introduced CARESAFE IV Administration Sets with an entirely voluntary AirStop component.
Intravenous Solution Market Segmentation
Intravenous Solution Nutrition Type Outlook
- Peripheral Parenteral Nutrition
- Total Parenteral Nutrition
Intravenous Solution Bag Type Outlook
- Large Volume Bags (>250 ml)
- Small Volume Bags (<250 ml)
Intravenous Solution End User Outlook
- Hospital & Clinics
- Ambulatory Surgical Centers
- Home Care
Intravenous Solution Nutritional Content Outlook
- Amino Acid Solution
- Carbohydrates
- Vitamins & Minerals
- Parenteral Lipid Emulsion
- Others
Intravenous Solution Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
